108061-23-0

Basic information

• Product Name: L-2-(benzyloxy)-4-methylpentanoic acid
• Synonyms: L-2-(benzyloxy)-4-methylpentanoic acid
• CAS NO: 108061-23-0
• Molecular Weight: 222.284
• Mol File: 108061-23-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: L-2-(benzyloxy)-4-methylpentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: L-2-(benzyloxy)-4-methylpentanoic acid(108061-23-0)
• EPA Substance Registry System: L-2-(benzyloxy)-4-methylpentanoic acid(108061-23-0)

Safety Data

• Hazardous Substances Data: 108061-23-0(Hazardous Substances Data)

Upstream product

• 17392-84-6 methyl L-2-hydroxy-4-methylpentanoate 
• 7722-84-1 dihydrogen peroxide 
• 108061-34-3 (S)-methyl 2-benzyloxy-4-methylpentanoate 
• 13748-90-8 (S)-2-hydroxyl-3,3-dimethylbutyric acid 
• 100-39-0 benzyl bromide 
• 108061-34-3 methyl L-2-(benzyloxy)-4-methylpentanoate 

Downstream Products

• 108061-24-1 methyl (L-2-(benzyloxy)-4-methylpentanoyl)-L-alaninate 
• 1053247-46-3 (2R,4S)-4-((S)-2-Benzyloxy-4-methyl-pentanoylamino)-1-(4-butoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 147324-73-0 (2S)-2-benzyloxy-4-methylpentanoic acid-(1S)-(1-formyl-3-methylthio)propylamide 

Relevant articles and documents

Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines

A series of hydroxamates was prepared from an aminoproline scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for five enzymes within the MMP family, and a number of inhibitors, such as compound 47, display broad-spectrum activity with sub-nanomolar potency for some enzymes. Modifications of the P1′ portion of the molecule played a key role in affecting both potency and selectivity within the MMP family. Longer-chain aliphatic substituents in this region of the molecule tended to increase potency for MMP-3 and decrease potency for MMP-1, as exemplified by compounds 48-50, while aromatic substituents, as in compound 52, generated broad-spectrum inhibition. The data is rationalized based upon X-ray crystal data which is also presented. While the in vitro peroral absorption seemed to be less predictable, it tended to decrease with longer and more hydrophilic substituents. Finally, a rat model of osteoarthritis was used to evaluate the efficacy of these compounds, and a direct link was established between their pharmacokinetics and their in vivo efficacy.

PEPTIDE AND PEPTIDE ANALOG PROTEASE INHIBITORS

Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: STR1 in which R 1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R. sub.2, R 4, and R 8 are each independently methyl or ethyl; R 3 is preferably iso-butyl or phenyl; R 5 is preferably iso-butyl; R 6 is H or methyl; R 7--(Q) n is preferably benzyloxycarbonyl or acetyl; Q is preferably--C(O)--; R 8 is preferbly iso-butyl; R A =--(T) m--(D) m--R 1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C 3-4 alkenyl being more preferred; and X is preferably an α-ketoester or α-ketoamide.

Synthesis and Chemical Properties of Tetrazole Peptide Analogues

Tetrazole dipeptide analogues in which the amide bond is replaced with the tetrazole ring were synthesized from the corresponding Z or Pht protected dipeptide esters via the imidoyl chloride and imidoyl azide intermediates.Of the various imidoyl chloride/